Acquisition Enhances Potential for pre-Clinical Services

Integrated drug discovery and pre-clinical services company Sygnature Discovery has expanded its oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for biotechs, pharmaceutical companies and academics. Prior to the take-over Alderley Oncology was run by Bruntwood SciTech, owners of Alderley Park. The value of the deal has not been disclosed.

Alderley Oncology was established by Jane Kendrew in 2017. Jane and the team have a wealth of experience in the field, much of it gained at AstraZeneca. “We are delighted to be joining Sygnature Discovery,” she said.  “We look forward to working with them as part of the wider team serving the oncology drug discovery community and patients living with cancer.’

"We are pleased to welcome Jane and her colleagues to Sygnature Discovery," said Dr Stuart Onions, Director of Research Management at Sygnature. "The team’s expertise in oncology and immuno-oncology in vivo models will significantly enhance our integrated oncology provision, delivering further value to our integrated projects for clients and importantly, allows us to more efficiently and effectively deliver potential new therapeutics into pre-clinic development."

The deal complements the 2018 acquisition of Nottingham-based RenaSci, which added complementary in vivo expertise in abuse and dependence, metabolic diseases, CNS disorders, and liver and kidney disease to Sygnature’s in vitro services.